What's Going On With G1 Therapeutics Stock?
Portfolio Pulse from Erica Kollmann
G1 Therapeutics, Inc. (NASDAQ:GTHX) shares surged amid M&A speculation of a takeover offer, reportedly rejecting multiple bids from TerSera Therapeutics. Trading volume spiked significantly, with over 25.4 million shares traded, far exceeding the 100-day average. Analysts from Needham and HC Wainwright & Co. maintain Buy ratings with price targets of $12 and $9, respectively. The average 1-year price target for GTHX is $10.17, indicating a potential upside of 75.65%.
May 09, 2024 | 6:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
G1 Therapeutics' stock price surged following rumors of a takeover offer by TerSera Therapeutics, with significant trading volume and bullish analyst ratings.
The surge in GTHX's stock price is directly attributed to the speculation of a takeover offer by TerSera Therapeutics, which has led to increased trading volume and investor interest. Analyst ratings from Needham and HC Wainwright & Co. support a bullish outlook, further influencing the stock's short-term trajectory.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100